Proteasome inhibitors in cancer therapy

被引：0
|
作者：
Romaniuk, Wioletta [1 ]
Oldziej, Agnieszka Ewa [1 ]
Zinczuk, Justyna [2 ]
Kloczko, Janusz [1 ]
机构：
[1] Uniwersytet Med Bialymstoku, Klin Hematol, Pododdzialem Chorob Naczyn, Bialystok, Poland
[2] Uniwersytet Med Bialymstoku, Zaklad Patomorfol Ogolnej, Bialystok, Poland
来源：
POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ | 2015年 / 69卷
关键词：
proteasome; carfilzomib; ixazomib; delanzomib; oprozomib; marizomib; SINGLE-AGENT CARFILZOMIB; CELLS IN-VITRO; IRREVERSIBLE INHIBITOR; PRECLINICAL MODELS; ANTITUMOR-ACTIVITY; DRUG-RESISTANCE; MULTIPLE; LENALIDOMIDE; COMBINATION; CEP-18770;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Proteasomes are multisubunit enzyme complexes. They contain three enzymatic active sites which are termed chymotrypsin-like, trypsin-like, and caspase-like. The elementary function of the proteasomes is degradation of damaged proteins. Proteasome inhibition leads to accumulation of damaged protein, which leads to caspase activation and cell death. This relationship is used in cancer therapy. Bortezomib is the first proteasome inhibitor approved by the US Food and Drug Administration for the treatment of relapsed/refractory multiple myeloma. Carfilzomib belongs to the second generation of drugs, which was approved by the US FDA in 2012. Currently in the study phase there are four new inhibitors: ixazomib (MLN9780/MLN2238), delanzomib (CEP-18770), oprozomib (ONX0912/PR-047) and marizomib (NPI-0052).
引用
收藏
页码：1443 / 1450
页数：8
相关论文
共 50 条
  • [1] The proteasome and proteasome inhibitors in cancer therapy
    Voorhees, PM
    Orlowski, RZ
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2006, 46 : 189 - 213
  • [2] Proteasome inhibitors in cancer therapy
    Crawford, Lisa J.
    Walker, Brian
    Irvine, Alexandra E.
    JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2011, 5 (02) : 101 - 110
  • [3] Proteasome inhibitors in cancer therapy
    Elisabet E. Manasanch
    Robert Z. Orlowski
    Nature Reviews Clinical Oncology, 2017, 14 : 417 - 433
  • [4] Proteasome inhibitors in cancer therapy
    Manasanch, Elisabet E.
    Orlowski, Robert Z.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (07) : 417 - 433
  • [5] Proteasome Inhibitors in Cancer Therapy
    Testa, Ugo
    CURRENT DRUG TARGETS, 2009, 10 (10) : 968 - 981
  • [6] Proteasome inhibitors in cancer therapy
    Lisa J. Crawford
    Brian Walker
    Alexandra E. Irvine
    Journal of Cell Communication and Signaling, 2011, 5 : 101 - 110
  • [7] Proteasome inhibitors for cancer therapy
    Iqbal, Mohamed
    McLaughlin, Patricia A. Messina
    Dunn, Derek
    Mallya, Satish
    Husten, Jean
    Ator, Mark A.
    Chatterjee, Sankar
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (07) : 2362 - 2368
  • [8] New proteasome inhibitors for cancer therapy
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (03) : 334 - 334
  • [9] The potential of proteasome inhibitors in cancer therapy
    Sterz, Jan
    von Metzler, Ivana
    Hahne, Jens-Claus
    Lamottke, Britta
    Rademacher, Jessica
    Heider, Ulrike
    Terpos, Evangelos
    Sezer, Orhan
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (06) : 879 - 895
  • [10] Proteasome inhibitors in cancer therapy: death by indigestion
    M Rossi
    A Oberst
    A Emre Sayan
    P Salomoni
    Cell Death & Differentiation, 2005, 12 (9) : 1255 - 1257
12345